PetVivo (PETVW) Stock Price, News & Analysis

Company Overview

PetVivo, Inc. (NASDAQ: PETVW) is a development-stage medical device company focused on creating novel hydrogel-based delivery systems for use in veterinary medicine. The company’s core technology leverages a porous, biocompatible polymer scaffold designed to entrap cells, small-molecule drugs or protein therapeutics and release them in a sustained manner within the joint space. By targeting degenerative conditions such as osteoarthritis, PetVivo aims to offer an alternative to traditional viscosupplementation and systemic therapies for animals.

At the heart of PetVivo’s offering is its proprietary injectable hydrogel platform, which is being evaluated for safety and efficacy in both large and small animal models. Preclinical data suggest that the matrix can preserve cell viability and maintain controlled release of active agents over weeks to months, potentially reducing the frequency of intra-articular injections. The company’s research programs currently focus on canine and equine joint disease, with plans to adapt the technology for additional species and therapeutic areas in the future.

Headquartered in Irvine, California, PetVivo conducts its research and development operations in the United States and has engaged with veterinary clinics and distribution partners to support early-stage studies. The company is also exploring regulatory pathways for clearance in North America and Europe, aiming to establish a commercial footprint once pivotal data are obtained. PetVivo’s development efforts are supported by collaborations with academic laboratories and contract research organizations specializing in veterinary therapeutics.

Founded on polymer science research, PetVivo continues to refine its hydrogel formulations and expand its intellectual property portfolio. While the company remains in the clinical development phase, its management team brings experience in medical device development, veterinary science and regulatory affairs. PetVivo’s long-term strategy is to transition its lead candidates through pivotal trials, secure market authorizations and build a scalable platform for next-generation sustained-release therapies in animal health.

Key Stats

• Today's Range: $0.0051 to $0.0051
• 50-Day Range: $0.01 to $0.04
• 52-Week Range: $0.01 to $0.10
• Volume: N/A
• Average Volume: 2,283 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PETVW
• CIK: 1512922
• Web: N/A
• Phone: 952-405-6216
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.05 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A